| ★ |  When to Add GLP-1 Receptor Agonists to Metreleptin in Lipodystrophy, With Lindsay Fourman, MD | | 44 | Estados Unidos | |
| 18 |  Rethinking GLP-1s: A Smarter Policy for Long-Term Metabolic Health | Metabolic Mind @metabolicmind | — | Estados Unidos | 86 |
| 14 |  GLP-1s: Overdosing, Side Effects & Long-Term Risks | Dr. Abud Bakri & Dr. Andrew Huberman | Huberman Lab Clips @hubermanlabclips | 237.4K | Estados Unidos | 87 |
| 19 |  Are GLP1’s For Everyone? Which One Is Right For You? | Talking With Docs @talkingwithdocs | 191.9K | Canadá | 86 |
| 11 |  GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals | Metabolic Mind @metabolicmind | 49.3K | Estados Unidos | 87 |
| 13 |  Muscle, metabolism & GLP-1s | Rocio Salas-Whalen, M.D. | the mindbodygreen podcast @mindbodygreen | 3.4K | Estados Unidos | 87 |
| 17 |  GLP1 Drugs Results Naturally...Is it Possible? #glp1 #news #naturalglp1 #cagrisema | Dr. G's Lifestyle Medicine Network @gooddrg | 3.2K | Estados Unidos | 87 |
| 15 |  CagriSema: The Next Gen GLP1? #glp1 #news #healthandwellnessforseniors #semaglutide #wegovy | Dr. G's Lifestyle Medicine Network @gooddrg | 3.2K | Estados Unidos | 87 |
| 7 |  Ask A Cardiothoracic Surgeon: Know When NOT to Use GLP-1 Drugs 🚫❤️ | Michael Richman MD, MMM, FACS @michaelrichmanmd | 2.9K | Estados Unidos | 88 |
| 5 |  GLP-1 Medications: What You Need to Know | DarioHealth @dariohealthwellbeing | 711 | Estados Unidos | 89 |
| 20 |  When Your Diabetes Medication is the Latest Craze: Updates and Navigating Drug Shortages | Stanford Health Care @stanfordhospital | 600 | Estados Unidos | 86 |
| 16 |  GLP-1 Therapies: Where We’ve Been & Where We’re Going | Conversations on Health Care @cohcpodcast | 541 | Estados Unidos | 87 |
| 6 |  GLP-1 Medications for Weight Loss: the Latest Research | DarioHealth @dariohealthwellbeing | 365 | Estados Unidos | 88 |
| 9 |  GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD | | 151 | Estados Unidos | 87 |
| 8 |  GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy | | 80 | Estados Unidos | 87 |
| 1 |  Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest | | 68 | Estados Unidos | 92 |
| 12 |  GLP-1 Discontinuation in Type 2 Diabetes: What Happens When Patients Stop? | | 64 | Estados Unidos | 87 |
| 4 |  METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy | | 57 | Estados Unidos | 89 |
| 3 |  Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 89 |
| 2 |  Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | 90 |
| 10 |  GLP-1 use in ALZHEIMER'S. What's the DATA say? #glp1 #alzheimer #insulin | Data Driven Doug @datadrivendoug | 19 | Estados Unidos | 87 |